Thematische Bibliographien / Drug delivery to brain

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte
  6. Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Drug delivery to brain“

Autor: Grafiati
Veröffentlicht am 28. Juni 2021
Zuletzt aktualisiert am 1. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Drug delivery to brain" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Drug delivery to brain"

1

Rahman, Ruman, Emma Campbell, Henry Brem, Monica Pearl, Jordan Green, Miroslaw Janowski, Piotr Walczak et al. „SCIDOT-08. CHILDREN’S BRAIN TUMOUR DRUG DELIVERY CONSORTIUM (CBTDDC)“. Neuro-Oncology 21, Supplement_6 (November 2019): vi274. http://dx.doi.org/10.1093/neuonc/noz175.1149.

Der volle Inhalt der Quelle
Annotation:
Abstract INTRODUCTION The brain tumour community has seen significant progress in the discovery of new therapeutic targets and anticancer drugs. Unfortunately, advances in how to deliver drugs to the brain lag behind. The blood-brain barrier restricts the entry of many small-molecule drugs and nearly all large molecule drugs that have been developed to treat brain disorders. METHODS Following an international CNS drug delivery workshop in 2016, we were awarded funding from Children with Cancer UK to launch the Children’s Brain Tumour Drug Delivery Consortium (CBTDDC; www.cbtddc.org; @cbtddc). RESULTS The CBTDDC launched in 2017 (in Europe and the US) to raise awareness of the challenge of drug delivery in childhood brain tumours, and to initiate and strengthen research collaborations to accelerate the development of drug delivery systems. We ran a Workshop on Drug Delivery to the Brain, attracting 52 delegates from the UK, Belgium, Spain and Portugal. We liaised with UK-based funders over the drug delivery agenda, and with UK policy makers. In the US, we jointly organised the SIGN2019 meeting and we are currently liaising with the leads of Project ‘All In’ DIPG about how we can lend our support to this project. As of June 2019, 150 individuals have registered with the consortium, representing researchers, clinicians, charities, patient groups and industry. These stakeholders represent 70 research institutions, covering 15 countries (France, UK, Italy, Sweden, The Netherlands, USA, Greece, Germany, Belgium, Cuba, Denmark, Spain, Portugal, Israel and Egypt). We host a freely accessible online collaborative research database, containing the details of over 70 researchers. CONCLUSION We believe that collaboration between clinicians and multi-disciplinary researchers is vital to solving the brain tumour drug delivery challenge. We hope to raise awareness of the CBTDDC, and to extend our invitation for collaborators to join the consortium, through SCIDOT’s unrivalled drug delivery platform.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Airan, Raag. „Stimulating brain drug delivery“. Science Translational Medicine 12, Nr. 564 (07.10.2020): eabe8119. http://dx.doi.org/10.1126/scitranslmed.abe8119.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Bodor, Nicholas, und Peter Buchwald. „Brain-Targeted Drug Delivery“. American Journal of Drug Delivery 1, Nr. 1 (2003): 13–26. http://dx.doi.org/10.2165/00137696-200301010-00002.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Hoag, Hannah. „Drug delivery: Brain food“. Nature 510, Nr. 7506 (Juni 2014): S6—S7. http://dx.doi.org/10.1038/510s6a.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Belmaker, R. H., und G. Agam. „Deep Brain Drug Delivery“. Brain Stimulation 6, Nr. 3 (Mai 2013): 455–56. http://dx.doi.org/10.1016/j.brs.2012.05.001.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Jiang, Xinguo. „Brain Drug Delivery Systems“. Pharmaceutical Research 30, Nr. 10 (07.08.2013): 2427–28. http://dx.doi.org/10.1007/s11095-013-1148-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Kumar, Pankaj, Varun Garg und Neeraj Mittal. „Nose to Brain Drug Delivery System: A Comprehensive Review“. Drug Delivery Letters 10, Nr. 4 (20.11.2020): 288–99. http://dx.doi.org/10.2174/2210303110999200526123006.

Der volle Inhalt der Quelle
Annotation:
Nose to brain drug delivery system is an interesting approach to deliver a drug directly in the brain through the nose. Intranasal drug delivery is very beneficial because it avoids first-pass metabolism and achieves a greater concentration of drugs in the central nervous system (CNS) at a low dose. This delivery system is used for the treatment of various neurological disorders such as Parkinson's disease, Alzheimer's disease, schizophrenia, dementia, brain cancer, etc. To treat such types of diseases, different formulations like nanoparticles (NPs), microemulsions, in situ gel, etc. can be used depending on the physiochemical properties of the drug. In this review, some essential characteristics related to the delivery of nose to the brain and their possible obstacles are underlined, which include anatomy and physiology of nose to brain delivery. This review also summarizes innovations from the past three to five years.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Joshi, Shailendra, Phillip M. Meyers und Eugene Ornstein. „Intracarotid Delivery of Drugs“. Anesthesiology 109, Nr. 3 (01.09.2008): 543–64. http://dx.doi.org/10.1097/aln.0b013e318182c81b.

Der volle Inhalt der Quelle
Annotation:
The major efforts to selectively deliver drugs to the brain in the past decade have relied on smart molecular techniques to penetrate the blood-brain barrier, whereas intraarterial drug delivery has drawn relatively little attention. Meanwhile, rapid progress has been made in the field of endovascular surgery. Modern endovascular procedures can permit highly targeted drug delivery by the intracarotid route. Intracarotid drug delivery can be the primary route of drug delivery or it could be used to facilitate the delivery of smart neuropharmaceuticals. There have been few attempts to systematically understand the kinetics of intracarotid drugs. Anecdotal data suggest that intracarotid drug delivery is effective in the treatment of cerebral vasospasm, thromboembolic strokes, and neoplasms. Neuroanesthesiologists are frequently involved in the care of such high-risk patients. Therefore, it is necessary to understand the applications of intracarotid drug delivery and the unusual kinetics of intracarotid drugs.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Bahadur, Shiv, Nidhi Sachan, Ranjit K. Harwansh und Rohitas Deshmukh. „Nanoparticlized System: Promising Approach for the Management of Alzheimer’s Disease through Intranasal Delivery“. Current Pharmaceutical Design 26, Nr. 12 (06.05.2020): 1331–44. http://dx.doi.org/10.2174/1381612826666200311131658.

Der volle Inhalt der Quelle
Annotation:
Alzheimer's disease (AD) is a neurodegenerative brain problem and responsible for causing dementia in aged people. AD has become most common neurological disease in the elderly population worldwide and its treatment remains still challengeable. Therefore, there is a need of an efficient drug delivery system which can deliver the drug to the target site. Nasal drug delivery has been used since prehistoric times for the treatment of neurological disorders like Alzheimer's disease (AD). For delivering drug to the brain, blood brain barrier (BBB) is a major rate limiting factor for the drugs. The desired drug concentration could not be achieved through the conventional drug delivery system. Thus, nanocarrier based drug delivery systems are promising for delivering drug to brain. Nasal route is a most convenient for targeting drug to the brain. Several factors and mechanisms need to be considered for an effective delivery of drug to the brain particularly AD. Various nanoparticlized systems such as nanoparticles, liposomes, exosomes, phytosomes, nanoemulsion, nanosphere, etc. have been recognized as an effective drug delivery system for the management of AD. These nanocarriers have been proven with improved permeability as well as bioavailability of the anti-Alzheimer’s drugs. Some novel drug delivery systems of anti-Alzheimer drugs are under investigation of different phase of clinical trials. Present article highlights on the nanotechnology based intranasal drug delivery system for the treatment of Alzheimer’s disease. Furthermore, consequences of AD, transportation mechanism, clinical updates and recent patents on nose to brain delivery for AD have been discussed.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Deepti R. Damle, Dr. Archana D. Kajale, Dr. Madhuri A. Channawar und Dr. Shilpa R. Gawande. „A review: Brain specific delivery“. GSC Biological and Pharmaceutical Sciences 13, Nr. 2 (30.11.2020): 068–79. http://dx.doi.org/10.30574/gscbps.2020.13.2.0349.

Der volle Inhalt der Quelle
Annotation:
The overall prevalence rate for CNS pathology has demonstrated that approximately more than one billion people are undergoing from disorders of central nervous system. The most distressing fact about delivery of drugs to the CNS is the presence of blood brain barrier that have a tendency to impair the drug distribution and denotes the major impediment for the development of CNS drugs. Neuropeptides and many drugs which are hydrophilic in nature possibly will encompass the intricacy while passing the blood brain barrier. The net amount of delivered drug (medicinal agent) and its capability to gain access to the pertinent target sites are the main considering points for CNS drug development. Brain targeted drug delivery to the brain is valuable in the diseases of brain. (Alzheimer’s diseases, meningitis, brain abscess, epilepsy, multiple sclerosis, neuromylitis optica, sleeping disorders etc). Whereby high concentration can be gained with lesser side effects that occur because of release of drugs. The simplest method of targeting to brain is to obtain a therapeutic. Brain targeting systems to remain in the brain region by crossing BBB and hence significantly helps in increasing therapeutic activity. There is an increasing attraction towards brain targeting and sue to its immense application in the treatment of various CNS diseases because mostly drugs are unable to cross the BBB. This review article discuss one of the novel technology “nanotechnology” and other aspects that has been developed to target the brain and possess various clinical benefits such as reduced drug dose, less side effects, non-invasive routed, and better patient compliance.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Drug delivery to brain"

1

Huynh, Grace. „Convection administered drug delivery to the brain“. Diss., Search in ProQuest Dissertations & Theses. UC Only, 2007. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3251934.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Boltman, Taahirah. „Liposomal drug delivery to brain cancer cells“. University of the Western Cape, 2015. http://hdl.handle.net/11394/4706.

Der volle Inhalt der Quelle
Annotation:
Master of Science (Nanoscience)
Neuroblastomas (NBs) are the most common solid extra-cranial tumours diagnosed in childhood and characterized by a high risk of tumour relapse. Like in other tumour types, there are major concerns about the specificity and safety of available drugs used for the treatment of NBs, especially because of potential damage to the developing brain. Many plant-derived bioactive compounds have proved effective for cancer treatment but are not delivered to tumour sites in sufficient amounts due to compromised tumour vasculature characterized by leaky capillary walls. Betulinic acid (BetA) is one such naturally-occurring anti-tumour compound with minimum to no cytotoxic effects in healthy cells and rodents. BetA is however insoluble in water and most aqueous solutions, thereby limiting its therapeutic potential as a pharmaceutical product. Liposomes are self-assembling closed colloidal structures composed of one or more concentric lipid bilayers surrounding a central aqueous core. The unique ability of liposomes to entrap hydrophilic molecules into the core and hydrophobic molecules into the bilayers renders them attractive for drug delivery systems. Cyclodextrins (CDs) are non-reducing cyclic oligosaccharides which proximate a truncated core, with features of a hydrophophilic outer surface and hydrophobic inner cavity for forming host-guest inclusion complexes with poorly water soluble molecules. CDs and liposomes have recently gained interest as novel drug delivery vehicles by allowing lipophilic/non-polar molecules into the aqueous core of liposomes, hence improving the therapeutic load, bioavailability and efficacy of many poorly water-soluble drugs. The aim of the study was to develop nano-drug delivery systems for BetA in order to treat human neuroblastoma (NB) cancer cell lines. This was achieved through the preparation of BetA liposomes (BetAL) and improving the percent entrapment efficiency (% EE) of BetA in liposomes through double entrapment of BetA and gamma cyclodextrin BetA inclusion complex (γ-CD-BetA) into liposomes (γ-CD-BetAL). We hypothesized that the γ-CD-BetAL would produce an increased % EE compared to BetAL, hence higher cytotoxic effects. Empty liposomes (EL), BetAL and γ-CD-BetAL were synthesized using the thin film hydration method followed by manual extrusion. Spectroscopic and electron microscopic characterization of these liposome formulations showed size distributions of 1-4 μm (before extrusion) and less than 200 nm (after extrusion). As the liposome size decreased, the zeta-potential (measurement of liposome stability) decreased contributing to a less stable liposomal formulation. Low starting BetA concentrations were found to be more effective in entrapping higher amounts of BetA in liposomes while the incorporation of γ-CD-BetA into liposomes enhanced the % EE when compared to BetAL, although this was not statistically significant. Cell viability studies using the WST-1 assay showed a time-and concentration-dependent decrease in SK-N-BE(2) and Kelly NB cell lines exposed to free BetA, BetAL and γ-CD-BetAL at concentrations of 5-20 ug/ml for 24, 48 and 72 hours treatment durations. The observed cytotoxicity of liposomes was dependant on the % EE of BetA. The γ-CD-BetAL was more effective in reducing cell viability in SK-N-BE(2) cells than BetAL whereas BetAL was more effective in KELLY cells at 48-72 hours. Exposure of all cells to EL showed no toxicity while free BetA was more effective overall than the respective liposomal formulations. The estimated IC₅₀ values following exposure to free BetA and BetAL were similar and both showed remarkable statistically significant decrease in NB cell viability, thus providing a basis for new hope in the effective treatment of NBs.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Lungare, Shital. „Development of novel delivery systems for nose-to-brain drug delivery“. Thesis, Aston University, 2017. http://publications.aston.ac.uk/37491/.

Der volle Inhalt der Quelle
Annotation:
The blood brain barrier (BBB) poses a significant hurdle to brain drug delivery. However, the location of the olfactory mucosa, within the nasal cavity, is a viable target site for direct nose-to-brain (N2B) delivery, thereby bypassing the BBB. To exploit this target site innovative nasal formulations are required for targeting and increasing residency within the olfactory mucosa. We developed and characterised three formulation systems for N2B delivery, (i) thermoresponsive mucoadhesion nasal gels sprays; (ii) mesoporous silica nanoparticles and (iii) nasal pMDI devices. We developed an optimal mucoadhesive formulation system incorporating amantadine as a model, water-soluble anti-Parkinson’s drug using carboxymethy cellulose and chitosan as mucoadhesives. Formulations demonstrated droplet sizes of < 130mm and stability over 8-weeks when stored at refrigeration conditions with no significant cellular toxicity against olfactory bulb (OBGF400) and nasal epithelial (RPMI 2650) cells. Mesoporous silica nanoparticles (MSNP) were prepared (~220nm) and demonstrated cellular uptake into OBGF400 within 2-hours of incubation with minimal toxicity. MSNP were loaded with two novel phytochemicals known to possess CNS activity, curcumin and chrysin, with loading efficiencies of ~12% confirmed through TGA, DSC and HPLC-UV analysis. Furthermore, a pH dependant release profile was identified with curcumin with greater release at nasal cavity pH 5.5 compared to pH 7.4. Furthermore, successful incorporation of MSNP into nasal gels was demonstrated through rheological studies with a decrease in Tsol-gel. A pilot study was conducted to assess the feasibility of modified existing pulmonary pMDI to deliver diazepam intranasally, targeting the olfactory mucosa. Diazepam was formulated with HFA134a and using ethanol as a co-solvent, and demonstrated stability in formulation over 3 months. Deposition studies within a nasal cast model demonstrated 5-6% deposition onto the olfactory mucosa under optimal administration conditions in the absence of any nozzle attachments. Our studies have provided a basis for the development to innovative intranasal formulation systems potentially capable of targeting the olfactory mucosa for both water soluble and poorly soluble drugs.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Charlton, Stuart Thomas. „Drug delivery to the brain via intranasal administration“. Thesis, University of Nottingham, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.275962.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Ibegbu, Madu Daniel. „Functionalised dextran nanoparticles for drug delivery to the brain“. Thesis, University of Portsmouth, 2015. https://researchportal.port.ac.uk/portal/en/theses/functionalised-dextran-nanoparticles-for-drug-delivery-to-the-brain(c2da4093-315e-4647-90e1-4340acf2b8bd).html.

Der volle Inhalt der Quelle
Annotation:
Towards the development of drug carriers that are capable of crossing the Blood Brain Barrier, the techniques of emulsion polymerisation and nanoprecipitation have been utilised to produce nanoparticulate carriers from a systematic series of alkylglyceryl dextrans (of two different average molecular weights, 6 kDa and 100 kDa) that had been functionalised with ethyl and butyl cyanoacrylates. Also, zero length grafting of polylactic acid to butyl, octyl and hexadecylglyceryl dextrans has allowed the preparation of polylactic acid-functionalised nanoparticles. All materials and derived nanoparticles have been characterised by a combination of spectroscopic and analytical techniques. The average size of nanoparticles has been found to be in the range 100-500 nm. Tagging or loading of the nanoparticles with fluorophores or model drugs allowed the preliminary investigation of their capability to act as controlled-release devices. The effects of an esterase on the degradation of one such nanoparticulate carrier have been studied. Testing against bend3 cells revealed that all materials display dose-dependent cytotoxicity profiles, and allowed the selection of nanocarriers that may be potentially useful for further testing as therapeutic delivery vehicles for conditions of the brain.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Ong, Qunya. „Local drug delivery for treatment of brain tumor associated edema“. Thesis, Massachusetts Institute of Technology, 2014. http://hdl.handle.net/1721.1/95865.

Der volle Inhalt der Quelle
Annotation:
Thesis: Ph. D., Harvard-MIT Program in Health Sciences and Technology, 2014.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 115-127).
Brain tumor associated edema, a common feature of malignant brain neoplasms, is a significant cause of morbidity from brain tumor. Systemic administration of corticosteroids, the standard of care, is highly effective but can introduce serious systemic complications. Agents that inhibit the vascular endothelial growth factor (VEGF) pathway, such as cediranib, are promising alternatives, but are also associated with systemic toxicity as VEGF is essential for normal physiological functions. A miniature drug delivery device was developed for local drug delivery in rodents. It comprises of a drug reservoir and a cap with orifice(s) through which drug is released. Drug release kinetics is dependent on the payload, the drug solubility, and the surface area for diffusion. Sustained releases of dexamethasone (DXM), dexamethasone sodium phosphate (DSP), and solid dispersion of cediranib (AZD/PVP) were achieved. Employing the solid dispersion technique to increase the solubility of cediranib was necessary to enhance its release. Therapeutic efficacy and systemic toxicity of local drug administration via our devices were examined in an intracranial 9L gliosarcoma rat model. Local delivery of DSP was effective in reducing edema but led to DXM induced weight loss at high doses in a pilot study. DXM, which is much less water-soluble than DSP, was used subsequently to reduce the dose delivered. The use of DXM enabled long-term, sustained zero-order release and a higher payload than DSP. Local deliveries of DXM and AZD/PVP were demonstrated to be as effective as systemic dosing in alleviating edema. Edema reduction was associated with survival benefit, despite continuous tumor progression. Animals treated with locally delivered DXM did not suffer from body weight loss and corticosterone suppression, which are adverse effects induced by systemic DXM. Local drug administration using our device is superior to traditional systemic administration as it minimizes systemic toxicity and allows increased drug concentration in the tumor by circumventing the blood brain barrier. A much lower dose can therefore be utilized to achieve similar efficacy. Our drug delivery system can be used with other therapeutic agents targeting brain tumor to achieve therapeutic efficacy without systemic toxicity.
by Qunya Ong.
Ph. D.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Sharma, Gitanjali. „Dual Modified Liposomes for Drug and Gene Delivery to Brain“. Diss., North Dakota State University, 2014. https://hdl.handle.net/10365/27310.

Der volle Inhalt der Quelle
Annotation:
The overall goal of our research was to design a vector for efficient delivery of therapeutic genes/drugs to brain. Specifically, this research work was focused on designing PEGylated liposomes surface modified with the receptor targeting protein, transferrin and cell penetrating peptides (CPPs) for targeting and improving the delivery of desired therapeutic agent to brain. Various CPPs including poly-L-arginine, TAT, Penetratin and Mastoparan were investigated for their influence on transport of transferrin receptor targeted liposomes across brain endothelial cells. The dual-modified liposomes were synthesized using thin film hydration and post-insertion technique. The biocompatibility of the liposomes was evaluated at increasing concentrations to obtain an optimum value for safe and effective delivery of drugs or genes. The liposomes showed excellent cellular, blood and tissue compatibility at the optimized concentration. In addition, the combination of targeting ligand transferrin and CPPs resulted in considerable translocation of the therapeutic agent across cellular and brain endothelial barriers both in vitro and in vivo. Among different Tf-CPP liposomes, the Tf-Penetratin liposomes showed maximum translocation of the drug across the brain endothelial barrier (approximately 15% across in vitro and 4% across in vivo BBB) and efficient cellular transport of the encapsulated drug (approximately 90-98%) in various cell lines. In addition, Tf-poly-L-arginine and Tf-Penetratin liposomes showed improved transfection efficiencies in various cell lines. The Tf-Penetratin and Tf-TAT liposomes demonstrated excellent cellular biocompatibility and no hemolytic activity upto 200nM phospholipid concentration. In vivo efficacy of the liposomes was evaluated by performing biodistribution studies in in adult Sprague Dawley rats. The liposomes were intended for delivery of small molecule drug, doxorubicin and pDNA to brain. The dual modified liposomes showed significantly (p<0.05) higher transport of encapsulated agents in rat brain as compared to single ligand (Tf) or plain liposomes. Histological examination of the tissues, from various organs, did not show any signs of toxicity including necrosis, inflammation, fibrosis etc. The study underlines the potential of bifunctional liposomes as high-efficiency and low-toxicity gene delivery system for the treatment of central nervous system disorders.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Bin, Bostanudin Mohammad Fauzi. „Butylglyceryl-modified polysaccharide nanoparticles for drug delivery to the brain“. Thesis, University of Portsmouth, 2016. https://researchportal.port.ac.uk/portal/en/theses/butylglycerylmodified-polysaccharide-nanoparticles-for-drug-delivery-to-the-brain(a91de9ba-3070-40a4-bf66-400f4d63027d).html.

Der volle Inhalt der Quelle
Annotation:
The limited access to the brain of a large number of therapeutic actives due to the presence of the blood-brain barrier (BBB) has led to intensive research toward the development of nanotechnology-based approaches. Polysaccharides such as chitosan, guar gum, pectin and pullulan have been selected as starting materials for this study due to their biocompatibility, biodegradability, good drug carrier properties, and ease of chemical modification with short chain alkylglycerol-like moieties (expected to enhance drug permeability through the BBB). A series of butylglyceryl-modified polysaccharides were prepared and characterised using chromatographic, spectroscopic and thermal analysis techniques prior to formulation into nanoparticles (NPs) by means of a selection of methods that include reverse emulsification, nanoprecipitation, and ionotropic gelation. Dynamic Light Scattering, Nanoparticle Tracking Analysis, Electrophoretic Mobility Measurements and Electron Microscopy were employed to characterise all NPs (overall size range 120–200 nm, and zeta potential values ranging from -27 to +39 mV). Modified pullulan (PUL-OX4) and guar gum (GG-OX4) NPs were found to be most stable at physiological pH (7.4), in contrast to chitosan (CS-OX4) NPs that demonstrated an increase in size as a result of aggregation. PUL-OX4 NPs (< 145 nm) had the highest Angiotensin II model peptide loading (8.46 %), while GG-OX4 NPs showed the highest loading degree with Doxorubicin (19.11 %) and Rhodamine B (3.78 %). Drug release studies demonstrated that PUL-OX4 NPs released fastest all the model actives tested, while GG-OX4 NPs were able to retain them for the longest period of time. The in vitro interactions of NPs with mouse brain endothelial cells (bEnd3) were investigated using a Transwell permeability model, with results suggesting an increased model membrane permeability in the presence of the modified polysaccharide nanoparticles. The cytotoxicity of these NPs at physiologically-relevant concentrations was studied using MTT assays; all NPs were non-toxic at concentration below 2 mg/mL, however a decrease in cell viability was noticed at higher concentrations. PUL-OX4 nanoparticles were found to be the least toxic, having the lowest LC50 value (9.48 mg/mL; for comparison, CS-OX4 has 7.30 mg/mL). Haemolysis study demonstrated that at concentration below 12 mg/mL, all the NPs studied did not induce a haemolysis effect significantly when compared to PBS control, however an increase in the effect was observed at higher concentration. PUL-OX4 nanoparticles exhibited the highest LC30 value of 19.87 mg/mL while the lowest value was exhibited by CS-OX4 nanoparticles (13.95 mg/mL). Confocal microscopy and flow cytometry investigations confirmed that all modified polysaccharide NPs were successfully taken up by bEnd3 cells, becoming localised in the cytoplasm.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Molnár, Éva. „Modified-chitosan nanoparticles for drug delivery through the blood-brain barrier“. Thesis, University of Portsmouth, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.494005.

Der volle Inhalt der Quelle
Annotation:
Towards the development of nanoparticulate carriers that cross the blood-brain barrier, a series of alkylglyceryl-modified chitosans with systematically varied degrees of grafting were prepared through synthetic steps that involved the protection of amino moieties via the formation of phthaloyl chitosan. The modified chitosans were formulated into nanoparticle using an ionic gelation technique employing sodium tripolyphosphate. Polymers were characterised by FTER, ¹H- and ¹³C-NMR, and by viscometry and GPC techniques. The size distribution profiles of nanoparticles were determined by dynamic light scattering.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Toman, Petr. „Nanoparticles from alkylglyceryl-modified polysaccharides for drug delivery to the brain“. Thesis, University of Portsmouth, 2012. https://researchportal.port.ac.uk/portal/en/theses/nanoparticles-from-alkylglycerylmodified-polysaccharides-for-drug-delivery-to-the-brain(7c977729-1e45-45d9-b826-f1729a8d784c).html.

Der volle Inhalt der Quelle
Annotation:
The loading of therapeutic actives into polymeric nanoparticles represents one of the approaches towards drug transport through the blood-brain barrier – the main obstacle to drug delivery into the central nervous system. The non-toxic, biocompatible and biodegradable polysaccharides chitosan and dextran were modified with permeation-enhancing alkylglyceryl pendant chains through reaction with epoxide precursors. The modified polysaccharides were characterised by spectroscopic methods (1H-, 13C-NMR and FT-IR). These polysaccharides were further formulated into nanoparticles using three methods, namely: nanoprecipitation, solvent displacement via dialysis and electrospraying. The resultant colloidal systems formed were characterised using Dynamic Light Scattering, Nanoparticle Tracking Analysis and Electrophoretic Mobility Measurements. Dried nanoparticles were further characterised by Scanning Electron Microscopy and Atomic Force Microscopy. Formulations of alkylglyceryldextran derivatives were found to be stable at the physiologically relevant pH of 7.4. Over the same range of pH values, formulations of alkyglyceryl-chitosans formed aggregates. Respectively dependent upon the method of formulation and the pH, nanoparticles from poly(lactic acid)-graft-butylglyceryl-modified dextran exhibited diameters in the range 100-400 nm and zeta potentials of between -15 and -30 mV. The preparation of nanoparticulate congeners that incorporated a fluorescent marker molecule (Doxorubicin, Rhodamine B or Fluorescein) allowed the studies of the capabilities of nanoparticles to accommodate and release a model therapeutic load. Rhodamine B-loaded nanoparticles further allowed the study of the uptake of nanoformulations by mouse (bEnd3) brain endothelial cells. The interactions of nanoparticles with modelled blood-brain barriers (mouse bEnd3 and human hCMEC/D3) were studied by Electric Cell Substrate Impedance Sensing and also by means of the Transwell model. Data from MTT and Presto Blue assays were consistent with the absence of nanoparticle-induced cytotoxic effects. An in ovo study that used 3-day chicken embryos indicated the absence of whole-organism acute toxicity effects but failed to unmask the biodistribution profile of nanoparticles. The results have shown that poly(lactic)-graftalkylglyceryl- modified dextran nanoparticles possess some promising features (size, stability, loading capacity, and toxicity) that render them candidates for further evaluation as biocompatible nanocarriers for drug delivery to the brain.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Drug delivery to brain"

1

Morales, Javier O., und Pieter J. Gaillard, Hrsg. Nanomedicines for Brain Drug Delivery. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-0838-8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Hammarlund-Udenaes, Margareta, Elizabeth C. M. de Lange und Robert G. Thorne, Hrsg. Drug Delivery to the Brain. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-9105-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Agrahari, Vivek, Anthony Kim und Vibhuti Agrahari, Hrsg. Nanotherapy for Brain Tumor Drug Delivery. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1052-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Peptide drug delivery to the brain. New York: Raven Press, 1991.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Hammarlund-Udenaes, Margareta, Elizabeth C. M. de Lange und Robert G. Thorne. Drug delivery to the brain: Physiological concepts, methodologies, and approaches. Herausgegeben von American Association of Pharmaceutical Scientists. New York: AAPS Press, 2014.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

G, De Boer A., Hrsg. Drug tranport(ers) and the diseased brain: Proceedings of the Esteve Foundation Symposium 11, held between 6 and 9 October 2004, S'Agaró (Girona), Spain. Amsterdam, Netherlands: Elsevier, 2005.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Gutiérrez, Lucía M. Neuro-oncology and cancer targeted therapy. New York: Nova Biomedical Books, 2010.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Holowka, Eric P., und Sujata K. Bhatia. Drug Delivery. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1998-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Wang, Binghe, Teruna J. Siahaan und Richard Soltero, Hrsg. Drug Delivery. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2005. http://dx.doi.org/10.1002/0471475734.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Schäfer-Korting, Monika, Hrsg. Drug Delivery. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-00477-3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Drug delivery to brain"

1

Potschka, Heidrun. „Targeting the Brain – Surmounting or Bypassing the Blood–Brain Barrier“. In Drug Delivery, 411–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-00477-3_14.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

O’Reilly, Meaghan A., und Kullervo Hynynen. „Ultrasound and Microbubble-Mediated Blood-Brain Barrier Disruption for Targeted Delivery of Therapeutics to the Brain“. In Targeted Drug Delivery, 111–19. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Hynynen, Kullervo. „Macromolecular Delivery Across the Blood–Brain Barrier“. In Macromolecular Drug Delivery, 175–85. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-429-2_13.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Guarnieri, Michael, Benjamin S. Carson und George I. Jallo. „Catheters for Chronic Administration of Drugs into Brain Tissue“. In Drug Delivery Systems, 109–17. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-210-6_4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Pardridge, William M. „Strategies for Drug Delivery through the Blood-Brain Barrier“. In Directed Drug Delivery, 83–96. Totowa, NJ: Humana Press, 1985. http://dx.doi.org/10.1007/978-1-4612-5186-6_6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

De La Fuente, Maria, Maria V. Lozano, Ijeoma F. Uchegbu und Andreas G. Schätzlein. „Chapter 7.3. Drug Delivery Strategies: Nanostructures for Improved Brain Delivery“. In Drug Discovery, 392–432. Cambridge: Royal Society of Chemistry, 2012. http://dx.doi.org/10.1039/9781849735292-00392.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Huile Gao und Xinguo Jiang. „Brain Delivery Using Nanotechnology“. In Blood-Brain Barrier in Drug Discovery, 521–34. Hoboken, NJ: John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118788523.ch24.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Khosa, Archana, Kowthavarapu V. Krishna, Sunil Kumar Dubey und Ranendra Narayan Saha. „Lipid Nanocarriers for Enhanced Delivery of Temozolomide to the Brain“. In Drug Delivery Systems, 285–98. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9798-5_15.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Greig, N. H. „Drug Delivery to Brain Tumors“. In New Directions in Cancer Treatment, 259–77. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83405-9_13.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Lalan, Manisha, Rohan Lalani, Vivek Patel und Ambikanandan Misra. „Brain Targeted Drug Delivery Systems“. In In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes, 237–82. Boca Raton : Taylor & Francis, 2018.: CRC Press, 2018. http://dx.doi.org/10.1201/b22448-8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Drug delivery to brain"

1

Quispe, Rodrigo, Jorge A. Trevino, Faizan Khan und Vera Novak. „Strategies for nose-to-brain drug delivery“. In the 8th International Workshop on Innovative Simulation for Healthcare. CAL-TEK srl, 2019. http://dx.doi.org/10.46354/i3m.2019.iwish.017.

Der volle Inhalt der Quelle
Annotation:
"Intranasal drug administration is an effective method that has shown promise for delivering drugs directly to the brain. This approach is associated with many challenges, and efficacy in bypassing blood-brain barrier (BBB) is debated. This review describes the pathways of nose-to-brain drug delivery, physicochemical drug properties that influence drug uptake through the nasal epithelium, physiological barriers, methods to enhance nose-to-brain absorption, drug bioavailability and biodistribution, and intranasal devices for nose-to-brain drug delivery. The mechanism of each device is described and supporting evidence from clinical trials is presented. This paper summarizes strategies involved in nose-to-brain drug delivery and provides evidence of potential efficacy of nose-braindelivery from clinical trials."
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ergin, Aysegul, Mei Wang, Shailendra Joshi und Irving J. Bigio. „Optical Monitoring of Tracers and Mitoxantrone in Rabbit Brain and the Variability in Blood-Brain Barrier Disruption“. In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2011. http://dx.doi.org/10.1364/omp.2011.omc3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Seekell, Kevin C., Spencer Lewis, Christy Wilson, Gerald Grant und Adam P. Wax. „Feasibility of Brain Tumor Delineation using Immunolabeled Gold Nanorods“. In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2013. http://dx.doi.org/10.1364/omp.2013.mw1c.3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

DePaoli, Damon, Nicolas Lapointe, Younès Messaddeq, Martin Parent und Daniel C. Côté. „Primate brain tissue identification using a compact coherent Raman spectroscopy probe“. In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2019. http://dx.doi.org/10.1364/omp.2019.ow4d.5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Chandra, D., und P. Karande. „Transferrin mediated drug delivery to brain“. In 2011 37th Annual Northeast Bioengineering Conference (NEBEC). IEEE, 2011. http://dx.doi.org/10.1109/nebc.2011.5778697.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Gradinaru, Viviana. „Visualizing the Activity and Anatomy of Brain Circuits: Optogenetic Sensors and Tissue Clearing Approaches“. In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2015. http://dx.doi.org/10.1364/omp.2015.jw2b.1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Gerega, Anna, Wojciech Weigl, Daniel Milej, Piotr Sawosz, Ewa Mayzner-Zawadzka, Roman Maniewski und Adam Liebert. „Multiwavelength time-resolved measurement of diffuse reflectance for brain oxygenation assessment during hypoxic challenge test“. In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2011. http://dx.doi.org/10.1364/omp.2011.omc4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Pishko, Gregory L., Morad Nasseri, Seymur Gahramanov, Leslie L. Muldoon und Edward A. Neuwelt. „Blood-Tumor Barrier Normalization Effects on Cytotoxic Drug Delivery to Brain Tumors“. In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14648.

Der volle Inhalt der Quelle
Annotation:
The blood-brain barrier (BBB) restricts delivery of anti-cancer drugs to brain tumors, but the leaky neovasculature of the blood-tumor barrier (BTB) permits systemically delivered cytotoxic agents to reach the tumor. Anti-angiogenic therapies such as bevacizumab (BEV) have been shown to “normalize” brain tumor vasculature,1 but the impact on chemotherapy delivery remains unclear.2 The goal of this study was to use magnetic resonance imaging (MRI) to investigate the consequences of BTB normalization, via BEV, on temozolomide (TMZ) chemotherapy. Non-invasive MRI techniques were used to track the transport of a chemotherapy surrogate, a low molecular contrast agent (Gd-DTPA), in an intracerebrally implanted human glioma. MRI-derived Gd-DTPA concentration curves were fit to a transvascular exchange model to measure vascular permeability changes and were used to quantify initial area under the gadolinium curve (IAUGC) over the course of treatment.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Wu, Shih-Ying, Samantha M. Fix, Christopher Arena, Cherry C. Chen, Wenlan Zheng, Oluyemi O. Olumolade, Virginie Papadopoulou, Anthony Novell, Paul A. Dayton und Elisa E. Konofagou. „Focused ultrasound-facilitated brain drug delivery using optimized nanodroplets“. In 2017 IEEE International Ultrasonics Symposium (IUS). IEEE, 2017. http://dx.doi.org/10.1109/ultsym.2017.8091719.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

McDannold, Nathan, Lisa Treat, Natalia Vykhodtseva und Kullervo Hynynen. „Targeted drug delivery in the brain via ultrasound-induced blood-brain barrier disruption“. In 2009 IEEE International Symposium on Biomedical Imaging: From Nano to Macro (ISBI). IEEE, 2009. http://dx.doi.org/10.1109/isbi.2009.5193156.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Drug delivery to brain"

1

Thayumanavan, Sankaran. Feedback Drug Delivery Vehicles. Fort Belvoir, VA: Defense Technical Information Center, Juni 2012. http://dx.doi.org/10.21236/ada577627.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Anderson, Burt, Richard Heller, Ed Turos und Mark Mclaughlin. Drug Discovery, Design and Delivery. Fort Belvoir, VA: Defense Technical Information Center, Juni 2012. http://dx.doi.org/10.21236/ada563482.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Agarwal, Jayant P., und Himanshu J. Sant. Drug Delivery for Peripheral Nerve Regeneration. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada613477.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Orwin, Elizabeth, Isabella Wulur, Nicole Esclamado und Madineh Sarvestani. Cell Delivery System for Traumatic Brain Injury. Fort Belvoir, VA: Defense Technical Information Center, März 2008. http://dx.doi.org/10.21236/ada482999.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Dotto, Gian P. Peptide-Targeted Drug Delivery to Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, Juli 1999. http://dx.doi.org/10.21236/ada373913.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Dotto, Gian P. Peptide-Targeted Drug Delivery to Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, Juli 2000. http://dx.doi.org/10.21236/ada392787.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Atif Syed, Atif Syed. Targeted Drug Delivery by using Magnetic Nanoparticles. Experiment, Juni 2013. http://dx.doi.org/10.18258/0788.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, Juli 2003. http://dx.doi.org/10.21236/ada418735.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, Juli 2002. http://dx.doi.org/10.21236/ada410175.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, Juli 2004. http://dx.doi.org/10.21236/ada435264.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Drug delivery to brain" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen Bücher
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie